Low utilisation of diabetes medicines in Iran, despite their affordability (2000-2012): a time-series and benchmarking study.
Bottom Line: While the affordability of novel insulin preparations improved over time, they were still unaffordable in 2012.This had occurred despite affordability of essential diabetes medicines in Iran.Appropriate policies are required to address the underutilisation of diabetes medicines in Iran.
Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.Show MeSH
Related in: MedlinePlus
Mentions: Benchmarking with OECD countries showed that Iran had a low A10 utilisation in 2011 (figure 3). The prevalence of diabetes in Australia, Finland, Germany, Spain and Estonia were similar to Iran in 2011 (8–10%). The utilisation of A10 medicines increased in all of these countries from 2000 to 2011 but the magnitude of growth was highest in Iran (430.7%). Nevertheless, the annual per capita A10 utilisation in Iran was consistently and substantially lower than those five countries during the benchmarking period (figure 4).
Affiliation: Research Center for Rational Use of Drugs, Tehran University of Medical Sciences, Tehran, Iran.